141 related articles for article (PubMed ID: 22490049)
1. Insight into eukaryotic topoisomerase II-inhibiting fused heterocyclic compounds in human cancer cell lines by molecular docking.
Taskin T; Yilmaz S; Yildiz I; Yalcin I; Aki E
SAR QSAR Environ Res; 2012; 23(3-4):345-55. PubMed ID: 22490049
[TBL] [Abstract][Full Text] [Related]
2. Some fused heterocyclic compounds as eukaryotic topoisomerase II inhibitors.
Pinar A; Yurdakul P; Yildiz I; Temiz-Arpaci O; Acan NL; Aki-Sener E; Yalcin I
Biochem Biophys Res Commun; 2004 Apr; 317(2):670-4. PubMed ID: 15063810
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
[TBL] [Abstract][Full Text] [Related]
4. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR study on heterocyclic topoisomerase II inhibitors using CoMSIA.
Tekiner-Gulbas B; Temiz-Arpaci O; Yildiz I; Aki-Sener E; Yalcin I
SAR QSAR Environ Res; 2006 Apr; 17(2):121-32. PubMed ID: 16644553
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of friedelan triterpenoid analogs with DNA topoisomerase IIα inhibitory activity and their molecular docking studies.
Mandal A; Ghosh S; Bothra AK; Nanda AK; Ghosh P
Eur J Med Chem; 2012 Aug; 54():137-43. PubMed ID: 22633831
[TBL] [Abstract][Full Text] [Related]
8. Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
Kashyap M; Kandekar S; Baviskar AT; Das D; Preet R; Mohapatra P; Satapathy SR; Siddharth S; Guchhait SK; Kundu CN; Banerjee UC
Bioorg Med Chem Lett; 2013 Feb; 23(4):934-8. PubMed ID: 23321564
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
Zhou Y; Xu X; Sun Y; Wang H; Sun H; You Q
Bioorg Med Chem Lett; 2013 May; 23(10):2974-8. PubMed ID: 23566520
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of 4β-carbamoyl epipodophyllotoxins as potential antitumour agents.
Kamal A; Kumar BA; Suresh P; Juvekar A; Zingde S
Bioorg Med Chem; 2011 May; 19(9):2975-9. PubMed ID: 21489802
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and topoisomerase II inhibitory and cytotoxic activity of oxiranylmethoxy- and thiiranylmethoxy-chalcone derivatives.
Na Y; Nam JM
Bioorg Med Chem Lett; 2011 Jan; 21(1):211-4. PubMed ID: 21115246
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, antitumor activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors.
Karki R; Park C; Jun KY; Jee JG; Lee JH; Thapa P; Kadayat TM; Kwon Y; Lee ES
Eur J Med Chem; 2014 Sep; 84():555-65. PubMed ID: 25062006
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.
Jun KY; Lee EY; Jung MJ; Lee OH; Lee ES; Park Choo HY; Na Y; Kwon Y
Eur J Med Chem; 2011 Jun; 46(6):1964-71. PubMed ID: 21419530
[TBL] [Abstract][Full Text] [Related]
14. Antitumor agents. Part 235: Novel 4'-ester etoposide analogues as potent DNA topoisomerase II inhibitors with improved therapeutic potential.
Xiao Z; Vance JR; Bastow KF; Brossi A; Wang HK; Lee KH
Bioorg Med Chem; 2004 Jun; 12(12):3363-9. PubMed ID: 15158805
[TBL] [Abstract][Full Text] [Related]
15. High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II-targeting drugs.
Lage H; Aki-Sener E; Yalcin I
Int J Cancer; 2006 Jul; 119(1):213-20. PubMed ID: 16450374
[TBL] [Abstract][Full Text] [Related]
16. 4β-[4'-(1-(Aryl)ureido)benzamide]podophyllotoxins as DNA topoisomerase I and IIα inhibitors and apoptosis inducing agents.
Kamal A; Suresh P; Ramaiah MJ; Srinivasa Reddy T; Kapavarapu RK; Rao BN; Imthiajali S; Lakshminarayan Reddy T; Pushpavalli SN; Shankaraiah N; Pal-Bhadra M
Bioorg Med Chem; 2013 Sep; 21(17):5198-208. PubMed ID: 23849207
[TBL] [Abstract][Full Text] [Related]
17. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological activities of topopyrones.
Zaleski PA; Maini R; Leiris SJ; Elban MA; Hecht SM
J Nat Prod; 2012 Apr; 75(4):577-85. PubMed ID: 22462811
[TBL] [Abstract][Full Text] [Related]
19. Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity.
Abdel-Aziz M; Park SE; Abuo-Rahma Gel-D; Sayed MA; Kwon Y
Eur J Med Chem; 2013 Nov; 69():427-38. PubMed ID: 24090914
[TBL] [Abstract][Full Text] [Related]
20. Discovery of dihydroxylated 2,4-diphenyl-6-thiophen-2-yl-pyridine as a non-intercalative DNA-binding topoisomerase II-specific catalytic inhibitor.
Jun KY; Kwon H; Park SE; Lee E; Karki R; Thapa P; Lee JH; Lee ES; Kwon Y
Eur J Med Chem; 2014 Jun; 80():428-38. PubMed ID: 24796883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
